Drug intelligence / Profile preview

UI123

Development stage: Preclinical
Lead developer: Korea United Pharm
Modality: Small Molecules

Overview

UI123 is a Korea United Pharm small-molecule incrementally modified drug candidate being developed as a new fixed-dose combination lipid-modifying therapy. The company’s pipeline places UI123 in formulation development and identifies it as a long-term lipid-modifying-agent program; its active constituents, pharmacologic targets, dosage form, route of administration, and detailed mechanism have not been publicly disclosed. ([kup.co.kr](https://www.kup.co.kr/research/pipeline/pipeline02.htm))

Brand names: Atorax-E
Other names: atorvastatin and ezetimibe combination

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)NPC1L1 (Niemann-pick C1-Like 1 transporter)

Beyond the preview

Go deeper on UI123.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UI123.

Explore the full profile